17 July 2018Americas

LSIPR 50 2018: Backing the innovators

Josh Makower, partner at venture capital investor New Enterprise Associates (NEA), has worked within life sciences for more than 20 years. He has learnt that “IP is a must” in the industry, due to the extensive time and costs involved in bringing a health product to market.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

Sandoz wins $137.2m payout for lost profits in generic launch

Dexcom suffers second patent revocation at hands of UPC

Sanofi signs global rights deal to develop rare cancer therapy

WBD to merge with firm to create ‘powerhouse’ practice

Novo Nordisk files fresh lawsuits to intercept Wegovy generics

AstraZeneca unit draws line under Samsung dispute

LSIPR 50 2018: Backing the innovators

Editor's picks

Editor's picks

More features